Alexander M. Castellino, PhD

Alexander Castellino is a freelance writer who has been writing in the oncology space for over 15 years. After graduating in the biological sciences, he decided that, for him, the pen was mightier than the bench. He started writing with Nature Biotechnology, contributing to their News in Brief. Alex writes across a wide variety of topics, and in oncology he works with the ASCO Daily News, Medscape Oncology, and Cancer Therapy Advisor. When he is not writing, Alex loves to read, cook, and travel.

Most Recent Articles by Alexander M. Castellino, PhD

Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis

Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis

By

A matching-adjusted indirect comparison concluded that ponatinib offers better disease control compared with bosutinib in certain patients.

A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy

A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy

By

Humans are used to seeing canines used as tools in forensics — their skills are often harnessed to smell out drugs or trail a criminal. Some dogs are even used to locate household pests. The use of canines to detect lung cancer from smell alone, however, is a new prospect for oncologists and their patients.

"Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline

"Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline

By

A preplanned exploratory analysis in a subset of patients from the phase 3 FLAURA study with CNS metastases at baseline shows "impressive" clinical activity in the CNS.

Novel Approaches for the Treatment of Primary Central Nervous System Lymphoma

Novel Approaches for the Treatment of Primary Central Nervous System Lymphoma

By

A review published in Blood highlights new approaches that are being investigated to treat PCNSL based on the mutational landscape and signaling pathways that are extant in the disease.

Janus Kinase Inhibitors for the Treatment of Myelofibrosis

Janus Kinase Inhibitors for the Treatment of Myelofibrosis

By

The identification of driver mutations in myelofibrosis has helped cement understanding of the pathophysiology of the disease and has kick-started the development of targeted therapies.

More Articles by Alexander M. Castellino, PhD

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs